Avadel Pharmaceuticals plc Overview
Valuation check: AVDL's P/E ratio is 431.08, above the Healthcare sector average of 27.28.
Get informed when a big investor buys or sells
+ Follow431.08
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Avadel Pharmaceuticals plc (AVDL) currently reports a P/E ratio of 431.08. That is above the Healthcare sector average of 27.28. Use the charts on this page to explore Avadel Pharmaceuticals plc's P/E ratio history and peer comparisons.
Avadel Pharmaceuticals plc's P/E ratio of 431.08 is higher than the Healthcare sector average of 27.28. That is roughly 1480.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Avadel Pharmaceuticals plc's market price to a fundamental measure such as earnings, sales, or book value. At 431.08, AVDL can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of 431.08, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.28. From there, open related valuation or income-statement pages for Avadel Pharmaceuticals plc, and consider following AVDL for alerts when major investors trade the stock.
Avadel Pharmaceuticals plc is classified in the Healthcare sector. On P/E ratio, it currently shows 431.08 versus a sector average near 27.28. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AVDL with unrelated industries.
